Figure 1 | Scientific Reports

Figure 1

From: Clonal dynamics monitoring during clinical evolution in chronic lymphocytic leukaemia

Figure 1

Schema of the inferred tumour clonal evolution path of the CLL patient 1. Sequential acquisition of somatic alterations in patient 1 leads to its genomic diversification. Exposure to successive chemotherapy, immunochemotherapy and allogeneic transplants would be associated with acquisition of new alterations and may profile the CLL landscape. FCR: fludarabine, cyclophosphamide, rituximab; R + LENA: rituximab plus lenalidomide; OFA-Benda: ofatumumab-bendamustine; DLI: donor lymphocyte infusion; DHA0X: high-dose cytarabine and oxaliplatin.

Back to article page